share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/12/19 06:04

Moomoo AI 已提取核心信息

Adial Pharmaceuticals entered into a Purchase Agreement with Alumni Capital LP on December 13, 2024, allowing the company to sell up to $5M of newly issued common stock, with an option to increase to $10M. The purchase price per share will be 97% of the lowest daily volume-weighted average price over a three-day trading period, with a minimum price of $0.55 per share.The agreement runs until December 31, 2026, with Adial maintaining full control over the timing and amount of sales. The company is limited to issuing 1,280,515 shares (19.99% of outstanding shares) unless stockholder approval is obtained. As consideration, Adial issued 68,807 commitment shares to Alumni Capital.Proceeds from any sales will be used for strategic opportunities, staff expansion, working capital, and general corporate purposes. The agreement replaces a previous arrangement with Alumni Capital dated May 31, 2023, which was terminated effective December 13, 2024.
Adial Pharmaceuticals entered into a Purchase Agreement with Alumni Capital LP on December 13, 2024, allowing the company to sell up to $5M of newly issued common stock, with an option to increase to $10M. The purchase price per share will be 97% of the lowest daily volume-weighted average price over a three-day trading period, with a minimum price of $0.55 per share.The agreement runs until December 31, 2026, with Adial maintaining full control over the timing and amount of sales. The company is limited to issuing 1,280,515 shares (19.99% of outstanding shares) unless stockholder approval is obtained. As consideration, Adial issued 68,807 commitment shares to Alumni Capital.Proceeds from any sales will be used for strategic opportunities, staff expansion, working capital, and general corporate purposes. The agreement replaces a previous arrangement with Alumni Capital dated May 31, 2023, which was terminated effective December 13, 2024.
Adial Pharmaceuticals于2024年12月13日与Alumni Capital LP签署了一份购买协议,允许公司出售最多500万美元的新发行普通股,且可选择增加至1000万美元。每股购买价格为三天交易期间最低日均成交量加权平均价格的97%,每股最低价格为0.55美元。该协议有效期至2026年12月31日,Adial将保留全权控制销售的时间和数量。除非获得股东批准,公司限于发行1,280,515股(19.99%的流通股),作为对价,Adial向Alumni Capital发行了68,807股承诺股票。任何销售所得将用于战略机会、员工扩张、营运资金和一般企业用途。该协议取代了与Alumni Capital于2023年5月31日签订的先前安排,该安排于2024年12月13日终止。
Adial Pharmaceuticals于2024年12月13日与Alumni Capital LP签署了一份购买协议,允许公司出售最多500万美元的新发行普通股,且可选择增加至1000万美元。每股购买价格为三天交易期间最低日均成交量加权平均价格的97%,每股最低价格为0.55美元。该协议有效期至2026年12月31日,Adial将保留全权控制销售的时间和数量。除非获得股东批准,公司限于发行1,280,515股(19.99%的流通股),作为对价,Adial向Alumni Capital发行了68,807股承诺股票。任何销售所得将用于战略机会、员工扩张、营运资金和一般企业用途。该协议取代了与Alumni Capital于2023年5月31日签订的先前安排,该安排于2024年12月13日终止。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息